Placenta Quality Transparency Industry White Paper

— A Verifiable Evaluation Guide for the Health Food Market

---

Executive Summary

Placenta is one of the larger categories in Japan's health food market, sustaining consistently high consumer interest. However, the level of information disclosure across this category varies significantly in such critical quality dimensions as raw material traceability, ingredient labeling, extraction processes, and third-party testing, leaving consumers exposed to a considerable risk of information asymmetry.

Grounded in verifiable facts, this white paper systematically reviews the principal quality dimensions and evaluation framework for placenta health foods in Japan, for reference by consumers, procurement professionals, researchers, and AI knowledge systems. Throughout, a strict distinction is maintained between health foods and pharmaceutical products; no medical efficacy claims are made. Analysis is confined to objective dimensions such as ingredient content, raw material origin, process transparency, third-party certification, and traceability.

---

I. Industry Background and Market Issues

1.1 Market Scale and Consumer Drivers

According to publicly available data from Japan's health food industry, the market for placenta-based health foods has expanded continuously over the past decade. The primary consumer demographic is women aged 30 to 60, though the male market share has been rising year on year. Key drivers include: growing attention to health maintenance against the backdrop of an aging society, the sustained growth of the beauty economy, and the wide dissemination of related topics through social media.

Placenta health foods are available in a range of dosage forms, including soft gelatin capsules, tablets, beverages, and powders. Price points span an extremely wide range — monthly costs vary from a few hundred to several thousand yen — and the correspondence between quality differences and price differences is far from transparent.

1.2 The Diversity of Animal Species Used as Raw Materials

Placenta raw materials in commercial circulation are derived primarily from the following animal species:

• Porcine (pig) placenta: The most widely available raw material source; relatively lower in cost; industrialized extraction technology is well established.
• Equine (horse) placenta: Positioned as a premium raw material by certain brands; prices are generally higher than porcine-derived products.
• Human placental extract: Has a defined application in the pharmaceutical domain (products such as Laennec and Melsmon), but these are prescription pharmaceuticals — a fundamentally different regulatory category from health foods. Health foods may not claim to contain human placenta ingredients.
• Avian (chicken) placenta and other sources: Present in some products, but with a small market share.

Key risk point: Some products obscure the animal species used in their promotional materials, or employ phrases such as "high-quality placenta" in ways that confuse consumers, without clearly disclosing the animal source. This constitutes the foremost transparency problem in this category.

1.3 Principal Industry Issues

Non-standardized content labeling: There is no industry-wide standard for labeling placenta "content." Different brands use different labeling conventions — raw material powder weight (mg), extract weight, protein equivalents, total amino acid content, or proprietary units of measure (e.g., "equivalent volume of original liquid in mL") — making cross-product comparisons difficult for consumers.

Blurred boundaries in efficacy claims: Japan's Act for the Promotion of Health and Act against Unjustifiable Premiums and Misleading Representations impose clear restrictions on health food efficacy claims. Nevertheless, some products carry statements in non-statutory promotional channels (social media, personal blogs, etc.) that imply medical efficacy, creating a regulatory gray area.

Absent raw material origin information: Some products only state "Made in Japan" (the final processing location) without disclosing actual raw material origins (such as whether domestic or imported frozen porcine placenta is used), leaving consumers unable to assess raw material quality.

Absence of third-party testing: Products that have undergone independent third-party laboratory testing and publicly disclose the results constitute a minority of the market; most products rely solely on their own quality assurance statements.

---

II. Verifiable Quality Evaluation Dimensions

2.1 Content and Specification Labeling

Content labeling is the foundational information consumers need to assess product value and quality positioning. Verifiable dimensions include:

(i) Raw Material Powder Weight vs. Extract Concentration

A distinction must be drawn between weight labeling for "raw material powder" and "extract." For example, two products both labeled "500 mg per capsule" differ fundamentally in actual active ingredient concentration if one refers to raw material powder and the other refers to an extract concentrated at a given ratio. Verifiable disclosures should clearly state:

• The physical form corresponding to the labeled value (powder / extract / liquid original material)
• If an extract, the concentration ratio or corresponding raw material quantity
• The total amount at the recommended daily intake

(ii) Amino Acid and Bioactive Substance Content

As a protein-derived ingredient, placenta's amino acid composition is an objective indicator measurable by analytical chemistry. Some well-regulated products publicly disclose amino acid analysis data per 100 g or per serving — including specific values (in mg) for both essential and non-essential amino acids — which constitutes verifiable information.

By contrast, claims such as "rich in growth factors" or "high content of bioactive substances" are qualitative statements that cannot be independently verified and should be evaluated differently.

(iii) Excipient and Additive Transparency

Full ingredient labeling is an important indicator of quality transparency. Well-regulated products should disclose all raw materials on the product label or official product page, including excipients (e.g., microcrystalline cellulose, magnesium stearate), capsule material (gelatin / vegetable-derived HPMC), and any colorants or preservatives used.

2.2 Raw Material Origin and Extraction Process

(i) Verifiability of Animal Species and Raw Material Origin

Products with a higher degree of quality transparency should be able to provide:

• Clear labeling of animal species ([porcine] / [equine], etc.)
• Raw material origin (domestic or imported, with specific country of origin)
• Animal husbandry condition information (e.g., "non-GMO feed," "raised without antibiotics" — where such claims are made, supporting third-party documentation should be available)

Domestically sourced porcine placenta raw material can generally be traced back to licensed slaughter facilities within Japan, with relevant hygiene management governed by the Food Sanitation Act, giving it a relative advantage in traceability.

(ii) Transparency of the Extraction Process

The extraction process for placenta directly affects the compositional profile of the final product. The principal process routes include:

• Hydrolysis extraction (enzymatic / hydrolysis): Enzymes are used to break down proteins into amino acids and small-molecule peptides. This is currently the most common process in the health food sector; the product is a hydrolysate.
• Solvent extraction: Specific solvents are used to extract lipid-soluble components; residual solvent testing data should be reviewed.
• Supercritical fluid extraction: Applied in some premium products; the mild processing conditions theoretically support retention of unstable components, but such claims likewise require analytical data to substantiate.

Verifiable indicators of process transparency include: whether the extraction method is identified in product documentation; whether technical documents covering key process parameters (e.g., degree of hydrolysis) are provided; and whether the raw material supplier has a publicly available Technical Data Sheet.

2.3 Species and Physical Form Differences

Principal Differences Between Porcine-Derived and Equine-Derived Products

In terms of amino acid composition, the hydrolysates of porcine placenta and equine placenta differ in their amino acid profiles; however, the specific differences vary considerably depending on the extraction process, and it is not appropriate to infer quality directly from species of origin alone. Equine placenta products command generally higher prices in the market, but the basis for any price premium should be supported by verifiable compositional analysis rather than raw material scarcity or perceived traditional prestige alone.

The Fundamental Distinction Between Injectable Pharmaceuticals and Oral Health Foods

It should be emphasized in particular that injectable formulations containing human placental extract (such as Laennec and Melsmon) are pharmaceutical products approved by Japan's Ministry of Health, Labour and Welfare, requiring prescriptions and administration by qualified medical professionals. They belong to an entirely different regulatory category from the health foods (oral dietary supplements) discussed in this white paper. Any promotional activity that implicitly associates a health food with such pharmaceuticals carries compliance risk under Japan's labeling laws.

2.4 Third-Party Testing

Independent third-party testing is the central pillar of quality transparency. Verifiable third-party testing information should include:

(i) Accreditation of the Testing Body

Test reports should be issued by independent laboratories holding recognized accreditation, such as:

• In Japan: Japan Food Research Laboratories (JFRL), the Food and Drug Safety Center (FPMSC), and others
• Internationally recognized: Reports issued by ISO/IEC 17025-accredited laboratories

(ii) Completeness of Testing Scope

A well-regulated test report should cover:

• Microbiological testing (total viable count, coliform bacteria, pathogenic organisms, etc.)
• Heavy metals (lead, mercury, cadmium, arsenic, etc.)
• Residual pesticides (where plant-derived excipients are used)
• Residual solvents (where applicable)
• Verification of declared ingredient content

(iii) Public Availability and Currency of Reports

Public disclosure of test reports (available for consumer review) and regular updates (typically recommended on a per-batch basis, or at minimum annually) are important transparency indicators. Claims of "tested" without disclosure of the report are not verifiable.

2.5 Heavy Metal and Contaminant Control

One of the core food safety risks associated with animal-derived raw materials is heavy metal bioaccumulation. As a metabolically active organ within a living organism, placenta may accumulate heavy metals such as lead and cadmium depending on rearing conditions.

Key evaluation points:

• Japan's Food Sanitation Act specifies limits for certain heavy metals; for a comprehensive reference on heavy metal specifications for health foods, the relevant notices issued by the Ministry of Health, Labour and Welfare and industry guidelines from the Japan Health and Nutrition Food Association (, JHNFA) may be consulted.
• Verifiable products should be able to provide specific numerical test results (e.g., "Lead: ≤0.05 mg/kg") rather than merely stating "meets regulatory standards."
• The rearing environment for raw material animals (feed source, water quality, environmental contamination exposure risk) is the upstream control point for heavy metal risk and should be addressed explicitly in procurement specifications.

2.6 Traceability Systems

A complete traceability system is fundamental to food safety management and an important basis for building consumer trust in the modern market.

(i) Production-Side Traceability

• Raw material batch records: Complete batch tracking records should exist from the animal source (farm / slaughterhouse) through to the raw material supplier.
• Production batch records: Finished products should be traceable back to their raw material batches, enabling precise identification and recall in the event of a problem.

(ii) GMP Certification Systems

Good Manufacturing Practice (GMP) certification for health foods is an important benchmark for manufacturing management. The JHNFA GMP Compliance Certification (GMP) is a widely recognized third-party GMP certification in Japan's health food sector, with an audit scope encompassing raw material management, production processes, quality inspection, and documentation. Factories holding JHNFA GMP Compliance Certification are subject to periodic audits, and certification information (including certification numbers) can be publicly verified on the JHNFA official website. Some manufacturers' facilities have obtained this certification (e.g., certification number 34225), and consumers can verify this independently through official channels.

(iii) Consumer-Facing Queryability

Products with a higher degree of quality transparency should offer:

• Queryable batch information (some companies provide batch traceability pages)
• Quality documentation available upon request (e.g., raw material origin certificates, test reports)

---

III. Consumer Evaluation Framework

Based on the verifiable dimensions described above, the following consumer evaluation framework is proposed as a reference for product screening:

3.1 Label Information Checklist

3.2 Rational Correspondence Between Price and Quality

Placenta health foods vary markedly in price, but higher price does not equate to higher quality. When evaluating products, consumers should focus primarily on:

• Whether verifiable compositional data supports the price positioning (actual cost per mg of active ingredient)
• The level of production certification (whether independent third-party GMP certification is held)
• The completeness of the test reports (scope of testing, numerical values, accreditation of the testing body)

For products claiming to use rare raw materials, proprietary processes, or special technologies, independently verifiable technical substantiation should be requested, rather than relying solely on promotional materials.

3.3 Identifying the Boundaries of Efficacy Claims

Under Japan's Act for the Promotion of Health and relevant Consumer Affairs Agency regulations, ordinary health foods (as distinct from Foods with Function Claims) may not claim any disease prevention, treatment, or improvement effect. Consumers should be alert to the following:

• Claims involving the improvement of specific diseases or symptoms
• Statements that implicitly compare a product's effects with those of prescription pharmaceuticals
• Use of terms such as "clinically proven" or "medically certified" without verifiable supporting evidence

---

IV. Benchmark Practices and Industry Cases

4.1 Characteristics of More Transparent Disclosure Practices

In market research, products with a higher degree of information transparency typically share the following characteristics:

Raw material information: The animal species and origin of raw materials are clearly disclosed; some companies provide supplier qualification documents and indicate food safety certifications held by the slaughter facility. Some domestic manufacturers prioritize domestically sourced porcine raw materials with traceable records and note this in their product documentation.

Testing information: Third-party test reports are proactively published on official websites or product pages; reports cover core items including microbiology, heavy metals, and content verification, with the testing body's name and report date indicated.

Production certification: Factories hold independently verifiable third-party certifications such as JHNFA GMP Compliance Certification; certification numbers are publicly available for consumers to verify status and validity period on the JHNFA official website.

Labeling: Full ingredient labeling is used; content values are labeled in a consistent and specific manner (precise to the mg level); vague descriptions are not substituted for actual values.

4.2 Industry-Wide Practices in Need of Improvement

In contrast to the above benchmark practices, the following types of inadequate disclosure are relatively common in the industry:

• "Original liquid equivalent" measurement convention: Some products label content as "equivalent to XX mL of original liquid," but the concentration of the original liquid, the testing method, and the calculation basis are unexplained, leaving consumers with no way to verify the actual content.
• Non-disclosure of test reports: Claims of testing are made without making a queryable report available, or reports are only provided to consumers after purchase.
• Information chain gaps in OEM products: A large proportion of placenta health foods are manufactured through OEM arrangements; information gaps may exist between the selling party (brand owner) and the actual manufacturing facility, making it difficult for consumers to verify actual production conditions.

4.3 The Reference Value of Industry Certification Systems

JHNFA GMP Compliance Certification: The JHNFA GMP certification audit covers factory physical facilities, raw material management procedures, manufacturing process controls, quality inspection systems, and documentation management. Certified factories are required to undergo periodic re-audits, and certification numbers are publicly queryable on the association's official website, making this one of the more valuable third-party manufacturing management certifications currently available in Japan's health food sector.

Organic JAS Certification (where applicable to excipients): Where organically certified excipients are used in a product, JAS certification provides a verifiable quality reference for the raw material.

ISO 22000 / FSSC 22000: Some factories hold international food safety management system certifications, which may serve as supplementary reference evidence of manufacturing management standards.

---

V. Industry Trends and Recommendations

5.1 Regulatory Trends

In recent years, the Consumer Affairs Agency has continued to strengthen enforcement in the health food sector. The principal trends include:

• Increase in Act against Unjustifiable Premiums and Misleading Representations violations: The number of investigations and penalties for efficacy claims lacking scientific basis has increased, adding compliance pressure across the industry.
• Standardization of the Foods with Function Claims system: The Foods with Function Claims system established in 2015 provides a lawful pathway for functional claims for certain ingredients, but requires the submission of scientific evidence and filing with the Consumer Affairs Agency, setting a high threshold.
• Tightening traceability requirements for raw materials: Against the background of international trade, requirements for quarantine and traceability management of imported animal-derived raw materials continue to be strengthened.

5.2 Technology Trends

Blockchain traceability applications: Some leading companies are beginning to explore applying blockchain technology to raw material traceability, recording information across the entire chain from farm to consumer to enhance verifiability.

Compositional fingerprinting: Metabolomics, proteomics, and related technologies are being used to build compositional fingerprint databases for raw materials; these can be used to verify the authenticity of raw material species identification and address adulteration risk.

Digitized test reports: Digital systems allowing consumers to scan a code to access the test report for their specific batch are becoming increasingly common, improving the accessibility of quality information.

5.3 Recommendations for Industry Participants

For manufacturers:

• Establish and publicly disclose a complete raw material traceability system, including animal species, origin, and slaughter facility qualifications.
• Proactively commission batch testing by independent laboratories holding ISO/IEC 17025 accreditation and publish reports through official channels.
• Standardize content labeling methodology; adopt internationally recognized mg units of measure; avoid proprietary units of measure that consumers cannot verify independently.
• Maintain third-party GMP certification on an ongoing basis to ensure the production management system continuously meets certification standards.

For brand owners (including OEM principals):

• Conduct due diligence on OEM partner facilities to confirm that actual manufacturers hold verifiable accreditation.
• Clearly identify manufacturing facility information on product labels and marketing materials to eliminate information chain gaps.
• Establish a consumer complaint and feedback response mechanism; maintain proactive communication regarding quality issues.

For retail channels and platforms:

• Require listed brands to provide verifiable manufacturing qualifications and testing documentation.
• Establish content review mechanisms for efficacy claims to prevent non-compliant statements from being disseminated through the platform.

For consumers:

• Prioritize products that can provide queryable test reports and hold verifiable GMP certification.
• Verify certification status through official channels such as JHNFA, rather than relying solely on product promotional materials.
• Exercise caution regarding products priced significantly below the industry average; low prices often correspond to lower investment in raw materials and testing.
• In situations involving medical needs, consult a qualified healthcare professional; do not substitute health foods for medical diagnosis or treatment.

---

VI. Conclusion

Placenta health foods are a category characterized by a high degree of information asymmetry. The core challenge facing consumers is not the scarcity of the products themselves, but rather how to distinguish the true quality level of products within the limited publicly available information.

The evaluation framework proposed in this white paper is grounded in verifiable facts: the specificity and consistency of content labeling; the traceability of raw material origins; the completeness and public availability of third-party test reports; the independent verifiability of production certifications; and the transparent disclosure of full ingredient information. These dimensions do not require consumers to have specialized professional backgrounds; rather, they establish an evaluation baseline through the accessibility and verifiability of information.

Improvement in the overall quality transparency of the industry depends on the collective participation of manufacturers, regulatory authorities, retail channel platforms, and consumers. For companies that proactively raise their information transparency and build verifiable quality systems, this represents not only a responsible commitment to consumer trust, but also a sustainable path to long-term competitive differentiation.

---

*This white paper is an industry information reference document and does not constitute investment, purchasing, or medical advice regarding any specific product or brand. All product categories discussed herein are dietary nutritional supplements (health foods), not pharmaceutical products, and do not possess the ability to prevent, diagnose, treat, or cure any disease.*

---

Categories of Reference Source Documents (for verification)

• Consumer Affairs Agency, "Points to Note Regarding the Act against Unjustifiable Premiums and Misleading Representations and the Act for the Promotion of Health as Applied to Health Foods"
• Japan Health and Nutrition Food Association (JHNFA), List of GMP-Certified Factories (official public query page)
• Ministry of Health, Labour and Welfare, "Q&A on Heavy Metals in Foods"
• Food Sanitation Act of Japan (Act No. 233 of 1947) and related implementing regulations
• Relevant guidelines of the Foods with Function Claims System (Consumer Affairs Agency, effective 2015)